` DIM (Sartorius Stedim Biotech SA) vs DAX Index Comparison - Alpha Spread

DIM
vs
DAX Index

Over the past 12 months, DIM has underperformed DAX Index, delivering a return of 5% compared to the DAX Index's 31% growth.

Stocks Performance
DIM vs DAX Index

Loading
DIM
DAX Index
Add Stock
www.alphaspread.com

Performance Gap
DIM vs DAX Index

Loading
DIM
DAX Index
Difference
www.alphaspread.com

Performance By Year
DIM vs DAX Index

Loading
DIM
DAX Index
Add Stock

Competitors Performance
Sartorius Stedim Biotech SA vs Peers

DAX Index
DIM
0KHE
TMO
DHR
207940
Add Stock

Sartorius Stedim Biotech SA
Glance View

Market Cap
18.9B EUR
Industry
Life Sciences Tools & Services

Sartorius Stedim Biotech SA has been weaving the intricate threads of biotechnology innovation into a fabric of global influence and success. Established as a pivotal player in the biopharmaceutical industry, Sartorius Stedim Biotech has carved out a niche by offering sophisticated products and solutions that cater to the unique needs of biopharmaceutical manufacturers. The company’s portfolio is a testament to the fusion of scientific ingenuity and relentless pursuit of quality. Spanning filtration and purification solutions, fermentation equipment, and fluid management systems, their offerings ensure that complex biological drugs, including vaccines and monoclonal antibodies, are produced efficiently and safely. Sartorius Stedim Biotech’s endeavor is not just about supplying equipment; it’s about providing integrated solutions that optimize the entire production process, ensuring consistency, scalability, and compliance in industries bound by strict regulatory oversight. The company generated revenue through its comprehensive range of products and services that address every step of the biomanufacturing process. Their business model hinges on fostering long-term relationships with clients by offering tailored solutions that enhance productivity and reduce time-to-market for new therapies. Beyond direct sales of high-value equipment, Sartorius Stedim Biotech also capitalizes on recurring revenue streams generated from consumables and maintenance services essential for the ongoing operation of their systems. By continuously innovating and expanding its product lines, the company stays at the forefront of technological advancements, enabling clients to tackle the ever-evolving challenges of bioproduction. As the global biopharmaceutical industry surges forward, driven by increasing demand for biologics, Sartorius Stedim Biotech remains poised to maintain its role as an indispensable ally to firms dedicated to transforming the health landscape through revolutionary therapies.

DIM Intrinsic Value
179.75 EUR
Overvaluation 7%
Intrinsic Value
Price
Back to Top